We have evaluated the effects of a single bolus dose of rocuronium 0.6 mg kg 91 (group 1, n : 10) or vecuronium 0.1 mg kg 91 (group 2, n : 10) on intracranial pressure (ICP), mean arterial pressure (MAP), cerebral perfusion pressure (CPP) and heart rate (HR) in 20 neurosurgical patients undergoing mechanical ventilation of the lungs during continuous sedation with sufentanil and midazolam. Before and after neuromuscular block using twice the ED90 of the blockers, ICP, MAP, CPP and HR were recorded continuously for 15 min. Treatment caused no significant changes in ICP, CPP or MAP and there was no evidence of histamine release.
For neurosurgery the use of drugs which do not increase or preferentially decrease intracranial pressure (ICP) is preferred. For emergency neurosurgery, rapid sequence intubation is often performed as fasting conditions in patients with subarachnoid haemorrhages, severe head injury or intracerebral bleeding are often unknown. Suxamethonium is often used to facilitate tracheal intubation because of its rapid onset, but it has the disadvantage of increasing intracranial pressure. 1 Other non-depolarizing agents such as vecuronium 1 2 and atracurium dibesylate 1 3-5 have no direct effect on ICP; however, their onset of action is considered too long for rapid sequence intubation. Rocuronium is a non-depolarizing neuromuscular blocking agent with a faster onset than all currently available non-depolarizing agents, approaching that of suxamethonium. 6 7 There are no previous studies of the effects of rocuronium on cerebral dynamics. Because of the rapid onset of action of rocuronium, 8 we have compared the effects of rocuronium with those of vecuronium on ICP, mean arterial pressure (MAP), cerebral perfusion pressure (CPP) (: MAP 9 ICP) and heart rate (HR) in neurosurgical patients.
Patients and methods
After approval from the local Ethics Committee, we studied 20 ASA I-III patients, aged 18-65 yr. Patients known or suspected of having neuromuscular disorders, metabolic diseases, impaired renal function or impaired hepatic function were excluded. As osteoclastical trepanation interferes with the normal relationship between MAP and ICP, such patients were also excluded from this study. Five patients did not meet the inclusion criteria and these were replaced in order to have a total of 10 evaluable patients in each group. The investigation was performed in the neurosurgical intensive care unit, on postoperative or conservatively treated patients (table 1) , after a stabilization period of at least 6 h without neuromuscular block. The lungs of all patients were ventilated in a volumecontrolled mode with an air-oxygen mixture ( Non-parametric analysis of variance (Friedman) was performed for HR, MAP, ICP and CPP in both the rocuronium and vecuronium groups followed by the multiple comparison Wilcoxon 
Results
Characteristics of the 20 patients in the two groups are shown in table 2. Baseline variables did not differ significantly between the two groups. The time course of ⌬ICP, ⌬CPP, ⌬MAP and ⌬HR during the 15-min study period is shown in figures 1 and 2. In the rocuronium group, the change in ICP from baseline varied from 93 to ;4 mm Hg and in the vecuronium group from 94 to ;2 mm Hg. There were no significant changes in ICP, MAP and CPP in each group even though MAP decreased slightly (4%) in the rocuronium group. Patients in the rocuronium group showed a slight (;7 (4) %) but significant (P : 0.003) increase in HR which peaked 5 min after drug administration and decreased thereafter to baseline values. HR did not change in patients in the vecuronium group. No patient had histamine-related symptoms or adverse clinical events. Mean maximum block in the rocuronium group was slightly lower than that in the vecuronium group (95.9 (3.1) % vs 100%; ns). The difference between the two groups in onset time (rocuronium 142 (62) s, vecuronium 192 (64) s; P : 0.04) was significant (table 2). 
Discussion
In this study ICP was measured after administration of rocuronium 0.6 mg kg 91 or vecuronium 0.1 mg kg 91 in adult neurosurgical patients undergoing mechanical ventilation and continuous sedation with sufentanil and midazolam. To avoid any impact of concomitant neuromuscular block during the study, only intermediate-acting neuromuscular blocking agents were used for tracheal intubation during the pre-study period. In this study we attempted to control and minimize confounding factors that could influence ICP. External stimuli such as noise, touch and tracheal suction which might alter ICP were either avoided or held constant during the study. Reliable monitoring of ICP with either an intraventricular or extradural probe was achieved as measurements were performed only after a stabilization interval of at least 6 h. Recording of ICP during surgery could have been confounded by surgical manipulation. ICP was measured extradurally in 12 and intraventricularly in eight patients. Although it has been shown that extradural pressure correlates closely with intraventricular pressure over a wide range in animals and in clinical practice, 13 we decided to include approximately the same number of patients with ICP measured extradurally and intraventricularly. As our study was undertaken in both six patients with extradural ICP measurement and four patients with intraventricular ICP measurement, a possible impact of measurement technique was excluded. However, both are accepted methods of ICP measurement and this study aimed to detect changes from baseline rather than absolute values. The non-parametric statistical analysis of choice to detect only changes in ICP from the baseline in a time span (figs 1, 2) was therefore the Friedman test.
We used sufentanil and midazolam for sedation. There is controversy on the effects of sufentanil on ICP but recent studies have shown that sufentanil exerts minimal influence on ICP. 14 In patients sedated adequately with sufentanil, concomitant haemodynamic changes 15 are critical for adequate CPP, therefore, the infusion rate of sedating drugs remained unchanged before and during the study.
There was no significant change from baseline in MAP in the two groups during the 15-min study. The rocuronium group showed a transient increase in HR ( fig. 1 ) which peaked 5 min after administration of the neuromuscular blocking agent. The fact that patients were stable before the beginning of the study might have contributed to the marked cardiovascular stability noted in this study. Increases in HR from baseline, probably because of a vagal blocking effect, did not exceed 7% and MAP did not decrease by more than 4% in the rocuronium group. These changes were not clinically important. Our results concur with a report on dose-related HR increases associated with rocuronium in humans. 16 17 As the drug possesses no ganglionic blocking effect or histamine-releasing properties, 18 19 a substantial decrease in MAP was unlikely. CPP is calculated from MAP and ICP, which were not influenced by either blocker and therefore CPP was not impaired.
A reduction in cerebral perfusion and venous blood return caused by coughing or poor synchronization with the ventilator results in increased cerebral oedema. In neurosurgical patients, neuromuscular block is important to avoid brisk bucking, straining and coughing during laryngoscopy and tracheal intubation. In neurological patients with severe head injuries or subarachnoid haemorrhages who are restless and demonstrate difficulty in artificial ventilation in spite of sedatives and analgesics, neuromuscular block may be the treatment of choice to prevent an increase in ICP. 20 21 It is known that tubocurarine may increase ICP 22 by ganglionic block which may also produce arterial hypotension. If an increase in ICP occurs concomitantly with a decrease in MAP, a substantial decrease in CPP occurs. In patients with disturbed autoregulation, increased MAP after administration of pancuronium could be a disadvantage. Atracurium has the potential to release histamine, but in humans as in animals, 4 23 atracurium has been shown to have minimal effect on ICP. Vecuronium does not induce histamine release nor does it change MAP or HR. In patients with brain tumours, vecuronium had minimal effects on ICP, 2 24 which was consistent with our results. From the point of view of direct cerebral effects, non-depolarizing neuromuscular agents, such as pancuronium, 3 25 vecuronium 1 2 24 and atracurium, that do not increase ICP, are appropriate for use during neurosurgical procedures and for intubation. Good-to-excellent intubating conditions should exist to limit the increase in ICP which may be caused by intubation. The use of suxamethonium to facilitate tracheal intubation in neurosurgical patients has been associated with an increase in ICP for 4-6 min. 1 26 The mechanism of this effect has been ascribed to transient EEG desynchronization secondary to muscle fasciculation and concomitant increase in cerebral blood flow and cerebral blood volume [27] [28] [29] [30] [31] and to a transient increase in intra-abdominal pressure caused by muscle fasciculations leading to increased central venous pressure and intracerebral venous pressure. 32 Thus the increase in ICP is thought to be specific for depolarizing neuromuscular blocking agents. The use of suxamethonium therefore has been declining in clinical neuroanaesthetic practice, with the exception of emergency situations, such as the patient with a full stomach in whom rapid sequence induction is recommended.
Rocuronium is the first non-depolarizing neuromuscular blocking agent with a rapid onset (approaching that of suxamethonium) and good-toexcellent intubating conditions. 6 7 The results of our study suggest that rocuronium may be used for neurosurgical patients without the risks associated with suxamethonium.
